

**Technology Advisory Committee C Interests Register**  
**Nusinersen for treating spinal muscular atrophy [TA588]**  
**Publication Date: 24/07/2019**

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Matt Stevenson	TAC Committee Member (C)	Direct - financial	Matt Stevenson declared that he works at the School of Health and Related Research which produced the Evidence Review Group report for this appraisal, although he was not directly involved in the development of the report.	May 2018	27 June 2018	May 2018	It was agreed that this declaration would not prevent Matt Stevenson from participating in the committee meeting.
Paul Tappenden	TAC Committee Member (C)	Direct – financial	Paul Tappenden declared that he is the ERG representative of this appraisal on behalf of the School of Health and Related Research.	Not specified	27 June 2018	Not specified	It was agreed that this declaration would prevent Paul Tappenden from participating in the committee meeting.
Rob Forsyth	TAC Committee Member (C)	Direct – non financial	<ul style="list-style-type: none"> <li>Rob Forsyth declared that he has limited direct involvement in the care of children with SMA (the clinical indication for Nusinersen).</li> <li>Rob Forsyth declared he has made a new diagnoses of SMA and he</li> </ul>	Not specified	27 June 2018	Not specified	It was agreed that these declarations would not prevent Rob Forsyth from participating in the committee meeting.

			has close clinical colleagues who manage children with SMA.				
			<ul style="list-style-type: none"> <li>Rob Forsyth declared that he organised a conference on behalf of the European Paediatric Neurology Society at which treatments in child neurology which include Nusinersen was discussed, although members did not receive external funding to attend the conference.</li> </ul>	Sept 2018	27 June 2018	Not specified	
Richard Nicholas	TAC Committee Member (C)	Direct - financial	Richard Nicholas declared that he has received funding for attending advisory boards and lectures for products related to Multiple Sclerosis by Biogen.	Not specified	23 October 2018	Not specified	It was agreed that this declaration would prevent Richard Nicholas from participating in the committee meeting.
Adnan Manzur	TAC Clinical expert	Direct - financial	Adnan Manzur declared that he received consultancy fees where he provided consultancy work and attended an advisory board by Biogen.	July 2017	27 June 2018	Not specified	It was agreed that this declaration would not prevent Adnan Manzur from participating in the committee meeting.
Gennadiy Ilyashenko	TAC Patient expert	Direct – non-financial	Gennadiy Ilyashenko declared that he is a board member of TreatSMA.	Not specified	27 June 2018	Not specified	It was agreed that this declaration would not prevent Gennadiy Ilyashenko from

							participating in the committee meeting.
--	--	--	--	--	--	--	-----------------------------------------